Implications of chronobiology for 5-fluorouracil (5-FU) efficacy.

[1]  S. Iacobelli,et al.  Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. , 1993, European journal of cancer.

[2]  F. Lévi,et al.  Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma. , 1993, European journal of cancer.

[3]  J. Kornhauser,et al.  Regulation of jun-B messenger RNA and AP-1 activity by light and a circadian clock. , 1992, Science.

[4]  A. Reinberg,et al.  A chronopharmacologic phase II clinical trial with 5‐fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer , 1992, Cancer.

[5]  G. Poston,et al.  Effect of colostomy on the circadian rhythm in DNA synthesis in the rat colon. , 1992, Chronobiology international.

[6]  F. Lévi,et al.  A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients. , 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[7]  B. Lemmer,et al.  Circadian changes in estimated hepatic blood flow in healthy subjects. , 1991, British journal of clinical pharmacology.

[8]  W R Brown,et al.  A review and mathematical analysis of circadian rhythms in cell proliferation in mouse, rat, and human epidermis. , 1991, The Journal of investigative dermatology.

[9]  R. Sothern,et al.  Circadian rhythm of cellular proliferation in the human rectal mucosa. , 1991, Gastroenterology.

[10]  O D Laerum,et al.  DNA synthesis in human bone marrow is circadian stage dependent. , 1991, Blood.

[11]  David C. Klein,et al.  Suprachiasmatic nucleus : the mind's clock , 1991 .

[12]  R. Diasio,et al.  Circadian variation of fluoropyrimidine catabolic enzymes in rat liver: possible relevance to 5-fluorodeoxyuridine chemotherapy. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[13]  R. Willén,et al.  Circadian variations in cell cycle phase distribution in a squamous cell carcinoma xenograft; effects of cisplatin and fluorouracil treatment. , 1992, In vivo.

[14]  A. Reinberg,et al.  Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice. , 1990, The Journal of pharmacology and experimental therapeutics.

[15]  F. Lévi,et al.  Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. , 1990, Journal of the National Cancer Institute.

[16]  A. Reinberg,et al.  Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  W. Hrushesky,et al.  Determination of the therapeutic index of floxuridine by its circadian infusion pattern. , 1990, Journal of the National Cancer Institute.

[18]  Michael R. Green,et al.  The Modulation of Fluorouracil With Leucovorin in Metastatic Colorectal Carcinoma A Prospective Randomized Phase III Trial , 1990 .

[19]  E. Nowakowska-Duława.  Circadian rhythm of 5-fluorouracil (FU) pharmacokinetics and tolerance. , 1990, Chronobiologia.

[20]  J. Dunlap.  Closely watched clocks: molecular analysis of circadian rhythms in Neurospora and Drosophila. , 1990, Trends in genetics : TIG.

[21]  F. Lévi,et al.  The influence of the athymic mutation nude on the components of the circadian rhythm of activity in mice. , 1990, Chronobiology international.

[22]  R. Diasio,et al.  Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. , 1990, Cancer research.

[23]  R. Diasio,et al.  Circadian variation of 5-fluorouracil catabolism in isolated perfused rat liver. , 1989, Cancer research.

[24]  W. Hrushesky,et al.  Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Laurie,et al.  Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  N. Petrelli,et al.  The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Reinberg,et al.  Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice. , 1989, Cancer research.

[28]  Robert B. Diasio,et al.  Clinical Pharmacology of 5-Fluorouracil , 1989, Clinical pharmacokinetics.

[29]  J G Fryer,et al.  A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. Lemmer.  Chronopharmacology : cellular and biochemical interactions , 1989 .

[31]  R. Waldrop,et al.  DNA synthetic activity in tumor-bearing mice. , 1989, Chronobiology international.

[32]  J. Misset,et al.  Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. , 1989, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[33]  W. Scheithauer,et al.  Phase II evaluation of 5-fluorouracil, folinic acid and cisplatin in advanced-stage colorectal adenocarcinoma. , 1989, Oncology.

[34]  R. Diasio,et al.  Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy. , 1988, Biochemical pharmacology.

[35]  F. Lévi,et al.  Circadian and seasonal rhythms in murine bone marrow colony-forming cells affect tolerance for the anticancer agent 4'-O-tetrahydropyranyladriamycin (THP). , 1988, Experimental hematology.

[36]  P. Loehrer,et al.  A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  F. Lévi,et al.  Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. , 1988, Cancer research.

[38]  C. Erlichman,et al.  A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  W. Hryniuk,et al.  Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. , 1987, Seminars in oncology.

[40]  J. Harvey,et al.  Pilot trial of prolonged continuous-infusion 5-fluorouracil and weekly cisplatin in advanced colorectal cancer. , 1987, Cancer treatment reports.

[41]  G. Peters,et al.  Diurnal variation in the therapeutic efficacy of 5-fluorouracil against murine colon cancer. , 1987, In vivo.

[42]  N. Petrelli,et al.  Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. , 1987, NCI monographs : a publication of the National Cancer Institute.

[43]  D. Priest,et al.  Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Misset,et al.  A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP). , 1986, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[45]  C. Infante-Rivard,et al.  MAINTENANCE CHEMOTHERAPY FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA: BETTER IN THE EVENING , 1985, The Lancet.

[46]  M. Kennedy,et al.  Comparison of the circadian variation in cell proliferation in normal and neoplastic colonic epithelial cells. , 1985, Cancer letters.

[47]  W. Hrushesky.  Circadian timing of cancer chemotherapy. , 1985, Science.

[48]  A. M. Casanovas,et al.  [Chronobiologic aspects of the effect of methotrexate on dihydrofolate reductase]. , 1985, Annales pharmaceutiques francaises.

[49]  M. Boon,et al.  5 Variations in Size and Glycogen Content of Exfoliating Epithelial Cells at Different Times of the Day , 1984 .

[50]  M. Minshull,et al.  The effect of time of administration of 5-fluorouracil on leucopenia in the rat. , 1984, European journal of cancer & clinical oncology.

[51]  E. R. Burns,et al.  Effect of biological time on the determination of the LD50 of 5-fluorouracil in mice. , 1984, Pharmacology.

[52]  E. Haus,et al.  Circannual variation of intestinal cell proliferation in BDF1 male mice on three lighting regimens. , 1984, Chronobiology international.

[53]  J. Misset,et al.  Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study. , 1982, Cancer treatment reports.

[54]  F. Lévi,et al.  Circadian stage dependence of cis-diamminedichloroplatinum lethal toxicity in rats. , 1982, Cancer research.

[55]  F. Lévi,et al.  Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. , 1982, Cancer research.

[56]  V. Popovic,et al.  Circadian rhythm and 5-fluorouracil toxicity in C3H mice. , 1982, Progress in clinical and biological research.

[57]  M. L. Gardner,et al.  Diurnal variation in the intestinal toxicity of 5-fluorouracil in the rat. , 1981, Clinical science.

[58]  P. Houghton,et al.  Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. , 1981, Cancer research.

[59]  J. Pauly,et al.  Circadian variation in cell division of the mouse alimentary tract, bone marrow and corneal epithelium , 1978, The Anatomical record.

[60]  H. Simpson,et al.  Circadian variation in colony-forming ability of presumably intact murine bone marrow cells. , 1975, Chronobiologia.

[61]  V. Vaitkevicius,et al.  Comparison of continuously infused 5‐fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma , 1975, Cancer.

[62]  F. Halberg,et al.  Increased Tolerance of Leukemic Mice to Arabinosyl Cytosine with Schedule Adjusted to Circadian System , 1972, Science.

[63]  A. Mauer,et al.  DIURNAL VARIATION OF PROLIFERATIVE ACTIVITY IN THE HUMAN BONE MARROW. , 1965, Blood.

[64]  E. Cronkite,et al.  Mitotic indices of human bone marrow cells. I. Number and cytologic distribution of mitoses. , 1962, Blood.

[65]  L. Scheving.  Mitotic activity in the human epidermis , 1959, The Anatomical record.